← Browse by Condition
Medical Condition

retinoblastoma

Total Trials
6
Recruiting Now
6
Trial Phases
EARLY_Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for retinoblastoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — retinoblastoma Clinical Trials

How many clinical trials are currently recruiting for retinoblastoma?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for retinoblastoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for retinoblastoma?
retinoblastoma research spans Phase 1 (2 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a retinoblastoma clinical trial?
Eligibility criteria for retinoblastoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
1
Top Sponsors
Eye & ENT Hospital of Fudan University 2 trials
St. Jude Children's Research Hospital 1 trial
Targeted Therapy Technologies, LLC 1 trial
National Cancer Institute (NCI) 1 trial
French Africa Pediatric Oncology Group 1 trial

Recruiting Clinical Trials

NCT06972602 EARLY_Phase 1
Recruiting
High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
Enrollment
10 pts
Location
China
Sponsor
Eye & ENT Hospital of Fudan Un...
View Trial →
NCT03050268
Recruiting
Familial Investigations of Childhood Cancer Predisposition
Enrollment
1,500 pts
Location
United States
Sponsor
St. Jude Children's Research H...
View Trial →
NCT06679634 Phase 2
Recruiting
Retinoblastoma Phase II Expanded Access Clinical Trial
Enrollment
30 pts
Location
United States
Sponsor
Targeted Therapy Technologies,...
View Trial →
NCT01109394
Recruiting
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
Enrollment
6,035 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT04425434
Recruiting
Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
Enrollment
3,000 pts
Location
Burkina Faso, Côte d...
Sponsor
French Africa Pediatric Oncolo...
View Trial →
NCT06424301 EARLY_Phase 1
Recruiting
Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
Enrollment
2 pts
Location
China
Sponsor
Eye & ENT Hospital of Fudan Un...
View Trial →

Related Conditions

neuroblastoma (2) retinoblastoma recurrent (1) acute leukemia (1) adenomatous polyposis (1) adrenocortical carcinoma (1) aml (1) bap1 tumor predisposition syndrome (1) carney complex (1) choroid plexus carcinoma (1) constitutional mismatch repair deficiency syndrome (1) diamond blackfan anemia (1) dicer1 syndrome (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology